ELI LILLY AND COMPANY Unamortized Debt Issuance Expense
ELI LILLY AND COMPANY (LLY) had Unamortized Debt Issuance Expense of $160.80 million as of 2024-12-31, per its 10-K filed 2025-02-19.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:UnamortizedDebtIssuanceExpense · last filed 2025-02-19
- 2024-12-31: Unamortized Debt Issuance Expense $160.80M.
- 2023-12-31: Unamortized Debt Issuance Expense $90.50M.
- 2022-12-31: Unamortized Debt Issuance Expense $77.20M.
- 2021-12-31: Unamortized Debt Issuance Expense $84.20M.
| Period end | Unamortized Debt Issuance Expense | Unamortized Debt Issuance Expense as first filed |
|---|---|---|
| 2024-12-31 | $160.80M 10-K · filed 2025-02-19 | |
| 2023-12-31 | $90.50M 10-K · filed 2025-02-19 | |
| 2022-12-31 | $77.20M 10-K · filed 2024-02-21 | |
| 2021-12-31 | $84.20M 10-K · filed 2023-02-22 | |
| 2020-12-31 | $89.10M 10-K · filed 2022-02-23 | |
| 2019-12-31 | $73.60M 10-K · filed 2021-02-17 | |
| 2018-12-31 | $28.40M 10-K · filed 2020-02-19 | $49.10M 10-K · filed 2019-02-19 |
| 2017-12-31 | $49.00M 8-K · filed 2019-10-24 | |
| 2016-12-31 | $37.50M 10-K · filed 2018-02-20 | |
| 2015-12-31 | $37.10M 10-K · filed 2017-02-21 | |
| 2014-12-31 | $20.40M 10-K · filed 2016-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |